Vosoughian Maryam, Saeedi Nima, Moshari Mohammadreza, Dabir Shideh, Dahi Mastaneh, Tabashi Soudeh, Haji Naghi Tehrani Khadijeh, Hajizadeh Nastaran
Anesthesiology Research Center, Department of Anesthesiology and Critical Care, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Anesthesiology and Critical Care, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Iran J Pharm Res. 2021 Fall;20(4):415-421. doi: 10.22037/ijpr.2021.115243.15266.
Propofol is a short-acting intravenous anesthetic that is commonly used for induction and maintenance of anesthesia. Subanesthetic low doses of propofol has also been used to treat intractable migraine attacks in emergency wards with dramatic results. However, there is little information on the long-term efficacy of this drug in migraine headaches. The aim of this nonrandomized prospective observational study was to assess the effect of propofol anesthesia on the pain severity and frequency of migraine attacks in a 6-month follow-up period after anesthesia in patients with migraine headaches. The study was conducted on 51 known cases of migraine ranging in age from 21 to 66 years. Before anesthesia, patients completed a questionnaire including their characteristics, pain intensity of the headache using a visual analog scale, and a number of headache repetitions per month. All patients received propofol as the main anesthetic agent. At the end of anesthesia, the total amount of propofol usage was recorded. Patients were then followed up by telephone in the first, third, and sixth months after anesthesia, and the severity and frequency of the headache were recorded. Pain intensity or pain frequency significantly improved in 22 patients (43.1%), remained unchanged in 24 (47%), and worsened in 5 cases (9.8%) 6 months after anesthesia compared to before the anesthesia. In conclusion, since about half of the patients had significant improvement in the headache, propofol anesthesia may be considered as an acceptable anesthetic method in patients with migraine.
丙泊酚是一种短效静脉麻醉剂,常用于麻醉诱导和维持。亚麻醉剂量的丙泊酚也已被用于急诊病房治疗难治性偏头痛发作,效果显著。然而,关于这种药物对偏头痛长期疗效的信息却很少。这项非随机前瞻性观察性研究的目的是评估丙泊酚麻醉对偏头痛患者麻醉后6个月随访期内偏头痛发作的疼痛严重程度和频率的影响。该研究对51例年龄在21至66岁之间的已知偏头痛病例进行。麻醉前,患者完成一份问卷,内容包括他们的特征、使用视觉模拟量表评估的头痛疼痛强度以及每月头痛发作次数。所有患者均接受丙泊酚作为主要麻醉剂。麻醉结束时,记录丙泊酚的总用量。然后在麻醉后的第一个月、第三个月和第六个月通过电话对患者进行随访,并记录头痛的严重程度和频率。与麻醉前相比,麻醉后6个月,22例患者(43.1%)的疼痛强度或疼痛频率显著改善,24例患者(47%)保持不变,5例患者(9.8%)病情恶化。总之,由于约一半的患者头痛有显著改善,丙泊酚麻醉可被视为偏头痛患者可接受的麻醉方法。